Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
Cognition Therapeutics (NASDAQ: CGTX) announced the completion of final patient visits in their Phase 2 SHIMMER study evaluating CT1812 for mild-to-moderate dementia with Lewy bodies (DLB). The company expects to report topline results in December 2024. The study was conducted in partnership with the National Institute of Aging and the Lewy Body Dementia Association. The trial aims to assess CT1812's tolerability profile and identify efficacy signals in cognition and function measures for DLB patients.
Cognition Therapeutics (NASDAQ: CGTX) ha annunciato il completamento delle visite finali con i pazienti nel loro studio di Fase 2 SHIMMER che valuta il CT1812 per la demenza da corpi di Lewy (DLB) di grado lieve-moderato. L'azienda prevede di riportare i risultati preliminari a dicembre 2024. Lo studio è stato condotto in collaborazione con il National Institute of Aging e la Lewy Body Dementia Association. L'obiettivo della sperimentazione è valutare il profilo di tollerabilità del CT1812 e identificare segnali di efficacia nelle misure di cognizione e funzione per i pazienti con DLB.
Cognition Therapeutics (NASDAQ: CGTX) anunció la finalización de las visitas a pacientes en su estudio de Fase 2 SHIMMER que evalúa el CT1812 para la demencia con cuerpos de Lewy (DLB) de leve a moderada. La compañía espera informar resultados preliminares en diciembre de 2024. El estudio se realizó en asociación con el National Institute of Aging y la Lewy Body Dementia Association. El ensayo tiene como objetivo evaluar el perfil de tolerabilidad del CT1812 e identificar señales de eficacia en las medidas de cognición y función para pacientes con DLB.
Cognition Therapeutics (NASDAQ: CGTX)는 레비 소체 치매(DLB)에 대한 CT1812의 평가를 포함하는 2상 SHIMMER 연구에서 최종 환자 방문이 완료되었음을 발표했습니다. 이 회사는 2024년 12월에 초기 결과를 발표할 예정입니다. 이 연구는 국립노화연구소(National Institute of Aging) 및 레비소체치매협회(Lewy Body Dementia Association)와 협력하여 진행되었습니다. 이번 시험의 목적은 CT1812의 내약성을 검토하고 DLB 환자에 대한 인지 및 기능 지표에서 효능 신호를 식별하는 것입니다.
Cognition Therapeutics (NASDAQ: CGTX) a annoncé l'achèvement des visites finales des patients dans son étude de Phase 2 SHIMMER évaluant le CT1812 pour la démence à corps de Lewy (DLB) légère à modérée. La société prévoit de communiquer les résultats préliminaires en décembre 2024. L'étude a été réalisée en partenariat avec le National Institute of Aging et l'Association de la démence à corps de Lewy. L'objectif de l'essai est d'évaluer le profil de tolérance du CT1812 et d'identifier des signaux d'efficacité dans les mesures cognitives et fonctionnelles des patients atteints de DLB.
Cognition Therapeutics (NASDAQ: CGTX) hat den Abschluss der letzten Patientenbesuche in ihrer Phase-2-Studie SHIMMER bekannt gegeben, die CT1812 zur Behandlung von leichter bis mittelschwerer Demenz mit Lewy-Körpern (DLB) bewertet. Das Unternehmen erwartet, die ersten Ergebnisse im Dezember 2024 zu berichten. Die Studie wurde in Partnerschaft mit dem National Institute of Aging und der Lewy Body Dementia Association durchgeführt. Ziel der Studie ist es, das Verträglichkeitsprofil von CT1812 zu bewerten und Wirksamkeitssignale in den kognitiven und funktionalen Messungen bei DLB-Patienten zu identifizieren.
- Phase 2 SHIMMER study reached completion milestone with all patient visits finalized
- Results timeline clearly defined for December 2024
- None.
Insights
The completion of patient visits in the Phase 2 SHIMMER study marks a significant milestone for Cognition Therapeutics, though investors should maintain measured expectations. CT1812 is being evaluated for dementia with Lewy bodies (DLB), the second most common type of progressive dementia after Alzheimer's. The December 2024 timeline for topline results provides a clear catalyst date.
The DLB treatment market represents a substantial opportunity with current therapeutic options. However, given CGTX's small market cap of
– Topline results in second dementia indication expected to be reported in December 2024 –
PURCHASE, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the last patient has completed their final clinic visit in the Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB). The Company anticipates that topline results will be available in December 2024.
“We would like to extend our appreciation to the patients and caregivers who participated in our study, without whom we would not have been able to accomplish this goal. In addition, we would like to thank our investigators, our partners at the National Institute of Aging and the Lewy Body Dementia Association (LBDA) and the greater DLB awareness community for their tireless commitment,” stated Anthony Caggiano, M.D., Ph.D., Cognition’s chief medical officer and head of R&D.
Lisa Ricciardi, Cognition’s president and CEO, concluded, “We look forward to reviewing the results of this study to enhance our understanding of CT1812’s tolerability profile and identify signals of efficacy across measures of cognition and function.”
About Dementia with Lewy Bodies (DLB)
Dementia with Lewy bodies is the second most common cause of dementia, affecting an estimated 1.4 million Americans. The disease is believed to be caused by a buildup of the protein α-synuclein, which aggregates in Lewy bodies, which are found within brain neurons. DLB is referred to as a “whole-body” disease, as it disrupts biological processes affecting autonomic, digestive, cognitive, and motor systems. Varied initial symptoms may include day-to-day fluctuations in alertness level, hallucinations, delusions, movement disorders and REM sleep disorder (acting out dreams while sleeping). Only a few symptomatic treatments for DLB are approved and currently there are no disease-modifying therapeutics.
About the SHIMMER Study
The SHIMMER study is a double-blind, placebo-controlled Phase 2 clinical trial that enrolled 130 adults with mild-to-moderate DLB. Participants were evenly randomized to receive either placebo or one of two oral once-daily doses of CT1812 (100 mg or 300 mg) for six months. Participants are assessed throughout the study using the Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE), which track cognitive performance; the Clinician Assessment of Fluctuation (CAF) to measure the frequency and duration of cognitive fluctuations; and the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, an objective assessment of parkinsonism.
The SHIMMER study is supported by a grant award from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately
About CT1812
CT1812 is an experimental orally delivered small molecule oligomer antagonist that penetrates the blood-brain barrier and binds selectively to the sigma-2 (σ-2) receptor complex, which is involved in the regulation of key cellular processes. These processes are disrupted by toxic interaction with Aβ or α-synuclein oligomers, oxidative stress and other disease drivers. The ensuing damage to sensitive synapses can progress to a loss of synaptic function, which manifests as cognitive impairment and disease progression.
Participants are currently being recruited in the START study (NCT05531656) of CT1812 in adults with early Alzheimer’s disease; and the MAGNIFY study (NCT05893537) in adults with geographic atrophy (GA) secondary to dry age-related macular degeneration. Enrollment has completed in the SHIMMER study (NCT05225415) in adults with dementia with Lewy bodies and the SHINE study (NCT03507790) in mild-to-moderate Alzheimer’s disease.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We currently are investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases that are functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at https://cogrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including CT1812 are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Global Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
This press release was published by a CLEAR® Verified individual.
FAQ
When will Cognition Therapeutics (CGTX) release SHIMMER study results for CT1812?
What is the purpose of Cognition Therapeutics' (CGTX) SHIMMER study?
What phase is Cognition Therapeutics' (CGTX) CT1812 study for DLB?
